A new study published in the journal of Public Library of Science found that the triglyceride levels of individuals with ...

This study highlights the efficacy of home-based tDCS in treating major depressive disorder, with significant improvements in ...

Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the ...

The app, called Rejoyn, is cleared as a supplement to currently approved therapies and works by using specifically designed ...

Mirtazapine is an FDA- approved, prescription-only medication for major depressive disorder in adults. The medication works by increasing certain hormones in the brain to improve mood. Whichever ...

Alto Neuroscience hit a bum note in an early test of its precision neuropsychiatry model. | Alto Neuroscience hit a bum note ...

New research underscores the role of the immune system in depression, linking inflammation to poor response to standard antidepressants and highlighting the importance of personalized medicine in ...

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...

About the SPN-820 Phase 2a Clinical Study The study is a Phase 2a open-label study in 40 subjects with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that ...

Acacia Clinics in Silicon Valley working to transform mental health care. He studied and served at Stanford, where he earned ...

The Boston-based biotech will use the new fundraise to develop its pipeline of drug candidates for conditions such as major ...